Novo Nordisk’s Global Pill Push Gains Medicare Lift and EU Clearance as South African Copy Debuts
Published on 07/19/2026 at 14:53 | Redaktion boerse-global.de
A flurry of regulatory and commercial developments this week underscores the breadth of Novo Nordisk’s strategy for its oral GLP-1 franchise, even as the stock took a modest breather. The Danish drugmaker is simultaneously rolling out a lower?priced authorized copy of Ozempic in South Africa, securing EU approval for the Wegovy pill, and benefiting from a new US Medicare pilot that caps patient copays for obesity drugs at $50 a month.
The Medicare initiative, effective July 1, 2026, runs through the end of 2027 and directly supports uptake of Wegovy and other GLP?1 therapies in the United States. Industry estimates now peg the global obesity?drug market at $73 billion by 2034, with longer?range projections topping $150 billion by 2035. This policy tailwind arrives as Novo’s oral Wegovy tablet has already notched more than three million prescriptions in the US since its January 2026 launch, capturing 89% of all oral GLP?1 scripts in the country. Four out of five new patients had never used a GLP?1 medicine before, and first?quarter pill revenue came in at double the initial forecast.
In Europe, the European Commission on July 15 granted marketing authorization for the 25?milligram oral Wegovy tablet across 27 member states plus Norway, Iceland, and Liechtenstein, alongside a new injectable version carrying 7.2 milligrams of semaglutide in a single?dose pen. The pill achieved a mean weight loss of roughly 17% in clinical trials, with one?third of participants shedding at least a fifth of their body weight, versus a 3% loss on placebo. Physicians caution that oral dosing is somewhat less potent than injections due to drug loss during ingestion, requiring patients to take it on an empty stomach and at least eight hours after the last meal. European market launches are slated for the second half of 2026.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Adding a further geographic string to its bow, Novo Nordisk will introduce Extensior, an authorized copy of Ozempic, in South Africa on July 27 via health?care partner Acino. The product uses the same active ingredient and manufacturing process as the original but at a lower price point, aimed at broadening access in a region where an unlicensed gray market for GLP?1s has flourished due to supply constraints. Exact pricing details are expected next week.
The competitive landscape, however, is intensifying. Eli Lilly secured US approval for its own oral contender Orforglipron in April 2026 and is expected to enter Europe sometime in 2027. In a large diabetes study, Orforglipron bested Novo’s oral semaglutid. Meanwhile, Novo’s dual?agonist CagriSema fell short of Lilly’s Zepbound in a head?to?head trial, a setback that has prompted the company to emphasize cardiovascular outcomes rather than weight loss alone as a differentiator.
On the trading floor, the shares closed Friday at €43.95, off 2.42% — a dip that looks like profit?taking after a 15.69% surge over the previous 30 days. The relative?strength index of 62.6 suggests the stock is approaching overbought territory without flashing a danger signal, and it continues to trade above both its 50?day and 200?day moving averages. The 52?week high of €60.95, reached in July 2025, remains a distant marker.
Investors now turn to the company’s first?half results due August 5. The consensus forecasts a 2.9% year?on?year revenue decline for the second quarter and a 15.5% drop in profit, implying that the oral Wegovy’s blockbuster start may be offset by headwinds in other business lines or pricing pressure. Whether the pill’s momentum can beat those expectations will be the key near?term catalyst for the stock.
Ad
Novo Nordisk Stock: New Analysis - 19 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
